Achieving Improved Survival Outcomes in Advanced Breast Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Effects of using app-based interventions on quality of life among breast cancer patients: a systematic review with meta-analysis.Annals of medicine · 2025
   Pooled it
2. Effectiveness of aerobic exercise intervention on cardiovascular disease risk in female breast cancer: a systematic review with meta-analyses.BMC public health · 2024
   Pooled it
3. Cost-effectiveness analysis of Anastrozole combined with Abemaciclib for the treatment of postmenopausal hormone receptor-positive advanced breast cancer.Cost effectiveness and resource allocation : C/E · 2025
   Article
4. Prognostic factors analysis and nomogram construction of breast cancer patients lung metastases and bone metastases.Surgery open science · 2025
   Article
5. Atrial fibrillation and breast cancer-Vicious twins? A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2023
   Article
6. Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.Breast care (Basel, Switzerland) · 2022
   Article
7. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.Journal of personalized medicine · 2020
   Article
8. Cardiovascular disease events within 5 years after a diagnosis of breast cancer.BMC cancer · 2020
   Article
9. Relevance of Membrane Contact Sites in Cancer Progression.Frontiers in cell and developmental biology · 2020
   Review
10. Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab.International journal of nanomedicine · 2020
    Article

Corrections and comments

• Comment on
  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as